Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Celsentri

CELSENTRI 20 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 35–36

HOS-118504 · Präparat HOS-094825

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 35 Efavirenz 600 mg QD Maraviroc AUC12: ↓ 0.55 CELSENTRI dose should be (maraviroc 100 mg BID) Maraviroc Cmax: ↓ 0.49 increased to 600 mg twice Efavirenz concentrations not daily when co-administered measured, no effect is expected. with efavirenz in the absence of a potent CYP3A4 inhibitor. For combination with efavirenz + PI, see separate recommendations below. Etravirine 200 mg BID Maraviroc AUC12: ↓ 0.47 Etravirine is only approved (maraviroc 300 mg BID) Maraviroc Cmax: ↓ 0.40 for use with boosted protease inhibitors. For combination Etravirine AUC12: ↔ 1.06 with etravirine + PI, see Etravirine Cmax: ↔ 1.05 below. Etravirine C12: ↔ 1.08 Nevirapine 200 mg BID Maraviroc AUC12: ↔ compared to Comparison to exposure in (maraviroc 300 mg Single historical controls historical controls suggests Dose) Maraviroc Cmax: ↑ compared to that CELSENTRI 300 mg historical controls twice daily and nevirapine Nevirapine concentrations not can be co-administered measured, no effect is expected. without dose adjustment. Protease Inhibitors (PIs) Atazanavir 400 mg QD Maraviroc AUC12 ↑ 3.57 CELSENTRI dose should be (maraviroc 300 mg BID) Maraviroc Cmax: ↑ 2.09 decreased to 150 mg twice Atazanavir concentrations not daily when co-administered measured, no effect is expected. with a PI; except in Atazanavir/ritonavir Maraviroc AUC12 ↑ 4.88 combination with 300 mg/100 mg QD Maraviroc Cmax: ↑ 2.67 tipranavir/ritonavir where the (maraviroc 300 mg BID) Atazanavir/ritonavir concentrations CELSENTRI dose should be not measured, no effect is expected. 300 mg BID. Lopinavir/ritonavir Maraviroc AUC12 ↑ 3.95 400 mg/100 mg BID Maraviroc Cmax: ↑ 1.97 (maraviroc 300 mg BID) Lopinavir/ritonavir concentrations not measured, no effect is expected. Saquinavir/ritonavir Maraviroc AUC12 ↑ 9.77 1000 mg/100 mg BID Maraviroc Cmax: ↑ 4.78 (maraviroc 100 mg BID) Saquinavir/ritonavir concentrations not measured, no effect is expected. Darunavir/ritonavir Maraviroc AUC12 ↑ 4.05 600 mg/100 mg BID Maraviroc Cmax: ↑ 2.29 (maraviroc 150 mg BID) Darunavir/ritonavir concentrations were consistent with historical data. Nelfinavir Limited data are available for co- administration with nelfinavir. Nelfinavir is a potent CYP3A4 inhibitor and would be expected to increase maraviroc concentrations. Indinavir Limited data are available for co- administration with indinavir. Indinavir is a potent CYP3A4 inhibitor. Population PK analysis in phase 3 studies suggests dose reduction of maraviroc when co-administered with indinavir gives appropriate maraviroc exposure.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) lopinavir (HOS-086269) atazanavir (HOS-086180) nelfinavir (HOS-084520) protease (HOS-085623) etravirine (HOS-088088) saquinavir (HOS-084522) darunavir (HOS-086181) efavirenz (HOS-087947) nevirapine (HOS-088064) ritonavir (HOS-084521) tipranavir (HOS-086184)